Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.brainresrev.2004.04.001
DC FieldValue
dc.titleNeuroprotection and peptide toxins
dc.contributor.authorRajendra, W.
dc.contributor.authorArmugam, A.
dc.contributor.authorJeyaseelan, K.
dc.date.accessioned2013-06-05T09:51:27Z
dc.date.available2013-06-05T09:51:27Z
dc.date.issued2004
dc.identifier.citationRajendra, W., Armugam, A., Jeyaseelan, K. (2004). Neuroprotection and peptide toxins. Brain Research Reviews 45 (2) : 125-141. ScholarBank@NUS Repository. https://doi.org/10.1016/j.brainresrev.2004.04.001
dc.identifier.issn01650173
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/38360
dc.description.abstractNeurodegeneration induced by excitatory neurotransmitter glutamate is considered to be of particular relevance in several types of acute and chronic neurological impairments ranging from cerebral ischaemia to neuropathological conditions such as motor neuron disease, Alzheimer's, Parkinson's disease and epilepsy. The hyperexcitation of glutamate receptors coupled with calcium overload can be prevented or modulated by using well-established competitive and non-competitive antagonists targeting ion/receptor channels. The exponentially increasing body of pharmacological evidence over the years indicates potential applications of peptide toxins, due to their exquisite subtype selectivity on ion channels and receptors, as lead structures for the development of drugs for the treatment of wide variety of neurological disorders. This review comprehensively highlights the overview of the diversity in the molecular as well as neurobiological mechanisms of different peptide toxins derived from venomous animals with particular reference to neuroprotection. In addition, the potential applications of peptide toxins in the diagnosis and treatment of neurological disorders such as neuromuscular disorders, epilepsy, Alzheimer's and Parkinson's diseases, gliomas and ischaemic stroke and their future prospects in the diagnosis as well as in the therapy are addressed. © 2004 Elsevier B.V. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.brainresrev.2004.04.001
dc.sourceScopus
dc.subjectDisorders of the nervous system
dc.subjectGlutamate
dc.subjectIon channels
dc.subjectNeuroprotection
dc.subjectPeptide toxins
dc.subjectTrauma
dc.typeReview
dc.contributor.departmentBIOCHEMISTRY
dc.description.doi10.1016/j.brainresrev.2004.04.001
dc.description.sourcetitleBrain Research Reviews
dc.description.volume45
dc.description.issue2
dc.description.page125-141
dc.description.codenBRERD
dc.identifier.isiut000222306800005
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.